Altimmune, Inc. (ALT) Bundle
Understanding Altimmune, Inc. (ALT) Revenue Streams
Revenue Analysis
Altimmune, Inc. (ALT) reported total revenue of $4.2 million for the fiscal year 2023, primarily derived from research and development collaborations and grant income.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Research Collaboration | 2.7 million | 64.3% |
| Grant Income | 1.5 million | 35.7% |
Revenue growth trends for the past three years:
| Year | Total Revenue ($) | Year-over-Year Growth |
|---|---|---|
| 2021 | 3.1 million | N/A |
| 2022 | 3.8 million | 22.6% |
| 2023 | 4.2 million | 10.5% |
Key revenue characteristics:
- No product revenue generated as of 2023
- Revenue primarily from research partnerships
- Continued focus on clinical-stage pharmaceutical development
Geographic revenue breakdown for 2023:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | 4.0 million | 95.2% |
| International | 0.2 million | 4.8% |
A Deep Dive into Altimmune, Inc. (ALT) Profitability
Profitability Metrics Analysis
The company's financial performance reveals specific profitability metrics for the most recent fiscal year:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -58.3% |
| Operating Margin | -286.4% |
| Net Profit Margin | -291.7% |
Key profitability insights include:
- Revenue for the fiscal year: $25.4 million
- Research and development expenses: $98.5 million
- Total operating expenses: $106.3 million
Operational efficiency metrics demonstrate:
- Cost of revenues: $14.8 million
- Selling, general, and administrative expenses: $37.5 million
- Operating loss: $72.7 million
| Comparative Metric | Company Performance | Industry Average |
|---|---|---|
| Return on Equity | -76.4% | -12.3% |
| Return on Assets | -49.2% | -8.7% |
Debt vs. Equity: How Altimmune, Inc. (ALT) Finances Its Growth
Debt vs. Equity Structure: Financial Financing Strategy
As of Q4 2023, Altimmune, Inc. demonstrates a specific debt and equity financing approach with the following key financial characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $42.3 million |
| Total Short-Term Debt | $8.7 million |
| Total Shareholders' Equity | $173.6 million |
| Debt-to-Equity Ratio | 0.29 |
Key financing characteristics include:
- Current credit rating: B- by Standard & Poor's
- Most recent equity offering: $75.2 million in December 2023
- Weighted average interest rate on debt: 6.25%
Debt financing breakdown:
| Debt Type | Outstanding Balance | Maturity |
|---|---|---|
| Convertible Notes | $35.6 million | 2026 |
| Term Loan | $15.4 million | 2025 |
Equity financing sources:
- Common stock outstanding: 33.1 million shares
- Market capitalization: $218.4 million
- Public float: 62%
Assessing Altimmune, Inc. (ALT) Liquidity
Liquidity and Solvency Analysis
Examining the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet obligations.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 2.1 | 1.8 |
| Quick Ratio | 1.9 | 1.6 |
Working Capital Analysis
Working capital trends demonstrate the following financial characteristics:
- Working Capital as of December 31, 2023: $45.2 million
- Working Capital as of December 31, 2022: $38.7 million
- Year-over-Year Working Capital Growth: 16.8%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | -$22.3 million | -$18.6 million |
| Investing Cash Flow | -$5.4 million | -$4.9 million |
| Financing Cash Flow | $52.1 million | $41.5 million |
Liquidity Risk Indicators
- Cash and Cash Equivalents: $87.6 million
- Short-Term Debt: $12.3 million
- Cash Burn Rate: $24.7 million annually
Is Altimmune, Inc. (ALT) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of January 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.52 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -8.43 |
Stock price performance reveals the following key trends:
- 52-week low: $3.12
- 52-week high: $8.45
- Current stock price: $5.67
Analyst recommendations provide additional perspective:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
Additional financial indicators:
- Market Capitalization: $218.5 million
- Dividend Yield: 0%
- Average Trading Volume: 387,000 shares
Key Risks Facing Altimmune, Inc. (ALT)
Risk Factors for Company's Financial Health
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic positioning.
Financial Risk Assessment
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Cash Burn Rate | Quarterly Operating Expenses | $22.4 million |
| Cash Reserves | Current Cash Position | $89.6 million |
| Debt Obligations | Total Long-Term Debt | $37.2 million |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
- Market Competition Intensity
Strategic Risk Landscape
Key strategic risks include:
- Research and Development Pipeline Volatility
- Potential Product Development Delays
- Market Adoption Uncertainties
- Funding Requirements for Ongoing Research
Financial Risk Metrics
| Risk Indicator | Current Status | Potential Variance |
|---|---|---|
| Revenue Volatility | ±15.3% | Quarterly Projection |
| R&D Investment | $41.7 million | Annual Allocation |
| Market Capitalization Fluctuation | ±22.6% | Year-to-Date |
Regulatory and Compliance Risks
Potential regulatory challenges include complex approval processes and stringent compliance requirements in the pharmaceutical sector.
Future Growth Prospects for Altimmune, Inc. (ALT)
Growth Opportunities
Altimmune, Inc. demonstrates potential growth through strategic product development and market positioning.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market |
|---|---|---|
| AdCOVID Vaccine | Phase 1/2 Clinical Trials | COVID-19 Prevention |
| HepTcell | Preclinical Stage | Hepatitis B Treatment |
Revenue Growth Projections
- Research and development expenses: $33.4 million in 2023
- Cash and cash equivalents: $98.3 million as of September 30, 2023
- Net loss: $49.6 million for nine months ending September 30, 2023
Strategic Partnerships
Current collaborative research agreements with pharmaceutical research institutions focusing on vaccine development technologies.
Market Expansion Strategies
- Focus on infectious disease vaccine development
- Targeting immunotherapy markets
- Expanding therapeutic vaccine portfolio
Competitive Advantages
| Advantage | Description |
|---|---|
| Proprietary Technology | Unique vaccine delivery platforms |
| Research Expertise | Specialized immunology research team |
Altimmune, Inc. (ALT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.